AAMC - Association of American Medical Colleges

11/18/2026 | News release | Distributed by Public on 11/18/2026 09:36

The complex link between GLP-1s and eating disorders

  • AAMCNews

The complex link between GLP-1s and eating disorders

GLP-1 receptor agonists have revolutionized the treatment of obesity and other metabolic diseases, but they also may trigger disordered eating.

Getty Images

By Beth Howard, Senior Writer
Nov. 18, 2026

Content warning: This article discusses eating disorders, including anorexia nervosa, bulimia, binge eating, and behaviors that may be distressing to people with a history of disordered eating.

In 2023, Penny Gautreaux, a licensed social worker in Tacoma, Washington, was prescribed Rybelsus, a GLP-1 (glucagon-like peptide-1 receptor agonist), to help control her diabetes. Soon after, she began to slip into familiar eating patterns. Gautreaux started skipping meals and seeing how long she could go without eating at all - hallmarks of her past battle with anorexia nervosa, an eating disorder characterized by severe food restriction that can have serious, and sometimes fatal, health impacts.

"The drug took away all of my natural hunger cues," says Gautreaux, 40. "It took away all my desire for food."

Gautreaux admits feeling thrilled when she began to lose weight - and she enjoyed the attention it drew. "You get so much positive praise when you're losing weight," she says.

But she began to see that the medication was threatening her hard-won recovery. "I was able to do it - to be on these drugs and gain the benefits - for about a year and a half before I realized if I keep at it, I'm going to end up sick."

Gautreaux also struggled with gastrointestinal distress, a common GLP-1 side effect. Those factors convinced her that the risks of the medication outweighed its benefits, and she stopped taking it.

"Yes, my A1C [a measure of blood sugar] went down, and I think these drugs have a place for diabetes," she says. "But specifically for someone who's experienced anorexia, [they] can be risky."

Gautreaux is one of a growing number of people who have experienced a resurgence of disordered eating or who have developed a new eating disorder on such medications, approved for the treatment of obesity and diabetes.

"We've seen more people with previous histories of anorexia nervosa who recovered but then ended up on GLP-1s for diabetes or obesity have a severe relapse of their disorder," says Aaron Keshen, MD, an associate professor in the Department of Psychiatry at Dalhousie Medical School and codirector of the Nova Scotia Eating Disorder Provincial Service in Halifax, Nova Scotia.

At the same time, some people with active eating disorders are seeking GLP-1s outside the doctor's office, some not disclosing their diagnosis online or otherwise misrepresenting their health status in order to access these powerful drugs.

"People with anorexia are adding them to their appetite and weight-regulation toolbox, and they're misusing the medications," says Cynthia M. Bulik, PhD, founding director of the UNC Center of Excellence for Eating Disorders and distinguished professor in the Department of Psychiatry at the UNC School of Medicine in Chapel Hill, North Carolina. "It's far too easy to get the medications through med spas, compounding pharmacies, and weight-loss programs."

In a recent Yale School of Medicine study in JAMA, 45 out of 49 websites contacted offered the study's secret shopper a prescription for a GLP-1 medication with few questions asked. Only about half of these sites asked about a history of eating disorders.

Keshen suspects the temptation to go on a GLP-1 may rise around the Thanksgiving holiday and other year-end festivities, which typically revolve around food - often a fraught time for people with eating disorders.

"At high-stress times like holidays, people who are prone to eating disorders may be more inclined to seek out the medications," he says.

The GLP-1-eating disorder connection

Approximately 1 in 8 American adults is currently taking a GLP-1 receptor agonist, such as Ozempic, Wegovy, or Mounjaro - medications that have revolutionized the treatment of obesity and diabetes. These medications have also proven effective for people with heart disease, liver disease, chronic kidney disease, and obstructive sleep apnea, and show promise for many other conditions.

Some 9% of Americans, or 28.8 million people, will have an eating disorder at some point in their lives. There are no good estimates on the numbers of people who have a relapse of an eating disorder or who experience a new eating disorder after starting GLP-1s, says Keshen. But according to a June study of those who have eating disorders, published in JAMA Psychiatry, 22% are currently using a GLP-1, with 32% having used one at some point.

"Roughly 10% of the participants reported that they had misused a GLP-1 medication, such as tampering with the syringe," says lead study author Nicholas C. Peiper, PhD, MPH, an associate professor in the Department of Epidemiology and Population Health at the University of Louisville School of Public Health and Information Sciences in Louisville, Kentucky. "People with eating disorders are accelerating the titration schedule and increasing the dose before they should."

Complicating the picture is emerging evidence that by blunting appetite and hunger signals, GLP-1s may actually hold benefits for people with some eating disorders.

"We've been hearing some amazing anecdotal reports from people with binge-eating disorder and bulimia nervosa [food binges alternated with vomiting or laxative abuse] that [GLP-1s have] had a remarkable effect on reducing the urge to binge, reducing binge eating, and just giving them the sense that their eating is under their own control," says Bulik.

Says Keshen, "It's a very nuanced, complicated topic, and we need more data to know what the risk is, who's at risk, and who potentially could benefit."

The biology of hunger

Understanding the link between GLP-1s and disordered eating is the first step in the process.

"The biology of eating disorders and the mechanism of GLP-1 agonists intersect," says Amanda Banks, MD, an internist at the Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center in Philadelphia and author of the book Hijacked: Anorexia Nervosa in the Age of GLP-1 Medications. She recently wrote about the issue for the New England Journal of Medicine.

The brain has a built-in system, called the melanocortin pathway, for regulating hunger and fullness, Banks explains. It senses the body's energy needs and adjusts appetite accordingly. Genetic changes in this pathway can contribute to obesity or, conversely, a naturally lower body weight. Research also suggests that the melanocortin pathway may play a role in anorexia nervosa.

"There's a lot of both human and animal data to suggest that the melanocortin pathway is involved in both obesity and anorexia," Banks says. "You can almost think of obesity and anorexia as opposite ends of a metabolic spectrum."

GLP-1 medications - synthetic versions of the natural gut hormone GLP - act on some of these same brain circuits, reducing hunger, increasing feelings of fullness, and calming food cravings.

The potency of the drugs is key to their potential promise as well as their risks. GLP that the body produces naturally has a relatively short-lived effect on satiety, Bulik says.

"There's a small rise in our native GLP toward the end of the meal and after a meal, and then it quickly dissipates into its component parts," she adds. "It's a short-term indicator that it's time to terminate your feeding episode. GLP-1 medications are biologically 10,000 times more powerful than native GLP and stay active for a week. We go from this mild postprandial rise and quick dissipation to this biological sledgehammer that keeps the hammer down for a long period of time. That's why [GLP-1s are] so effective, but it also goes hand in hand with their increased risk to people who are vulnerable to eating disorders."

A potential boon for binge eating

The quieting of hunger signals afforded by GLP-1s may have an upside for people with eating disorders that revolve around uncontrollable food binges. Preliminary research suggests it could be an effective treatment for binge-eating disorder and, by extension, bulimia nervosa.

The experience of Paige Gordon hints at the possibilities. The 45-year-old mother of two from Santa Cruz, California, author of the forthcoming book Searching for Full, slipped into a binge-eating spiral after she consumed a full package of Oreos one day at age 11.

"It really got out of control when I turned 16 and got my license, so I had freedom with food," she says. "I would go to the doughnut shop and eat two dozen doughnuts on my way to school."

Later she started purging after eating because she was afraid that she would die from obesity, and she was diagnosed with bulimia nervosa. Gordon tried nearly every form of therapy, including inpatient treatment, to conquer the problem but says, "I couldn't stop the compulsion, and I hated myself for it."

Four years ago, however, she heard a podcast of a woman on Ozempic for obesity who described how the drug had stopped the "food noise" in her head.

"I pulled over on the side of the road and started weeping," says Gordon, who subsequently got a prescription herself. "I had never heard someone describe my lived experience."

During her third week on the drug, she says, "I was eating a sandwich and suddenly I didn't have the urge to eat more. For the first time in my life, I felt satisfied. And I haven't binged or purged since starting the medication." She takes about half the dose of the drug prescribed to people trying to lose weight, and her weight has remained stable.

Experts agree that more research is needed before GLP-1s can be considered a treatment option for bulimia. Toward that goal, Keshen's research team has submitted a grant for a small feasibility study of GLP-1 medications in people with bulimic-spectrum disorders.

Addressing the challenges

In the meantime, there's a growing consensus that doctors who prescribe GLP-1 medications can do more to avoid triggering or exacerbating eating disorders in their patients. New guidelines from a group of leading clinicians and researchers with expertise in diabetes, obesity, and eating disorders, call for carefully screening patients for eating disorders before a prescription is written.

It doesn't have to be complicated. Existing tools include the five-question SCOFF questionnaire, Bulik says. Patients who screen positive for worrying behaviors should be referred to an eating disorder specialist, the guidelines suggest.

Monitoring patients over time is equally important, she continues, noting that many physicians prescribing GLP-1 medications have little experience recognizing eating disorders. For one thing, not all people with restrictive eating habits are underweight. Patients with atypical anorexia are of normal weight or overweight yet pursue a harmful pace of weight loss.

Potential warning signs that a patient is in trouble include weight loss beyond the original treatment goal, escalating exercise, and continued pursuit of weight loss despite health issues, Bulik says.

Having a history of an eating disorder doesn't necessarily rule out GLP-1 treatment, she adds. With appropriate precautions, some patients may still benefit.

Those who treat eating disorders are hopeful that the research underpinning the development of GLP-1s may lead to medications for eating disorders, which are badly needed, Banks says. Specifically, the growing understanding of brain pathways involved in appetite regulation could open the door to new treatments for anorexia nervosa - the most vexing eating disorder, with the highest mortality rates of all mental health conditions.

The disease has long been viewed primarily as a psychiatric illness, she notes, but research suggests it also has an important metabolic component. Future medications targeting the metabolic mechanisms involved in the disorder could potentially make weight restoration and recovery easier.

"There's not going to be a single magic bullet that takes care of everything," Banks says. "It's just too complex of an illness. But there is an opportunity to go after the metabolic piece in a way that hasn't been done before."

Beth Howard, Senior Writer

Beth Howard is a senior writer for AAMCNews. She can be reached at [email protected].

SHARE:
Topic:
AAMC - Association of American Medical Colleges published this content on November 18, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 18, 2026 at 15:37 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]